Market Overview

UPDATE: JP Morgan Upgrades Charles River Laboratories to Overweight on Risk/Reward

Share:
Related CRL
A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Yellen Speech
Earnings Scheduled For February 14, 2017
Charles River Laboratories Is A Wonderful Business At A Wonderful Price (Seeking Alpha)

JP Morgan raised its rating on Charles River Laboratories (NYSE: CRL) from Neutral to Overweight and increased its price target from $40 to $42.

JP Morgan commented, "Charles River Laboratories (CRL) hosted its annual December guidance call yesterday, reiterating 2012 estimates (albeit with some EPS softness) and introducing 2013 bottom-line estimates 4-5% below consensus in light of the AstraZeneca deal (for which costs will be realized before full revenue benefits). While the news was met with disappointment, with shares -9.4%, we now see risk/reward as favorable heading into 2013 given improving fundamentals (3-5% LC growth projected vs. 1% in 2012, negative growth in 2009-2011), continued cost discipline, and importantly, a 10% free cash flow yield."

Charles River Laboratories closed at $35.65 on Wednesday.

Latest Ratings for CRL

DateFirmActionFromTo
Jan 2017Evercore ISI GroupUpgradesHoldBuy
Dec 2016Goldman SachsUpgradesSellNeutral
Nov 2016BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!